Dual GO/LDHA-IN-1 

Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1^[1].

Dual GO/LDHA-IN-1 (Compound 2) potently inhibits hGO and hLDHA with selectivity for hLDHA over hLDHB (IC₅₀ for hGO = 1.1 μM, Kᵢ for hGO = 0.39 μM, IC₅₀ for hLDHA = 0.05 μM, Kᵢ for hLDHA = 0.04 μM, Kᵢ for hLDHB = 1.7 μM)^[1].
Dual GO/LDHA-IN-1 (10-50 μM; 24 h) reduces intracellular oxalate levels without cytotoxicity^[1].
Dual GO/LDHA-IN-1 (2-50 μM; 24 h) induces LDHA degradation via the autophagy-lysosomal pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dual GO/LDHA-IN-1 (20 mg/kg; p.o.; daily; 10 days) reduces hepatic LDHA abundance, urinary oxalate, and renal calcium-oxalate crystal deposition in Agxt^−/− mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

577.71

C₃₇H₃₉NO₅

O=C(O)C1=CC(C2=CC=C(/C=C/C(C3=CC=C(C#CCCCCNCC45CC6CC(C5)CC(C6)C4)C=C3)=O)O2)=CC=C1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Arias F, et al. Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1. J Med Chem. Published online January 2, 2026.  [Content Brief]